drugset / Trial / NCT00522249
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease progression of patients with metastatic Renal Cell Carcinoma. The first phase of this study will determine the best dose of Peg-Intron, Sunitinib and Tarceva when given in combination. The safety of giving these drugs in combination and response to treatment will also be examined.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-05
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | — | Oral |
| Subject | Sunitinib | Small molecule | — | Oral |
| Subject | interferon alfa-2b | Protein / enzyme biologic | — | Subcutaneous |